|
| | Publication Year | Title | Author(s) |
| 21 | 30-Jun-2020 | Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B. | Carlino, Matteo S; Menzies, Alexander M; Atkinson, Victoria G; Cebon, Jonathan S ; Jameson, Michael B; Fitzharris, Bernard M; McNeil, Catriona M; Hill, Andrew Graham; Ribas, Antoni; Atkins, Michael B; Thompson, John A; Hwu, Wen-Jen; Hodi, F Stephen; Guminski, Alexander; Kefford, Richard F; Wu, Haiyan; Ibrahim, Nageatte; Homet Moreno, Blanca; Long, Georgina V |
| 22 | 24-Jun-2020 | Distinctive subpopulations of stromal cells are present in human lymph nodes infiltrated with melanoma. | Eom, Jennifer; Park, Saem Mul; Feisst, Vaughan; Chen, Chun-Jen J; Mathy, Joanna E; McIntosh, Julie D; Angel, Catherine E; Bartlett, Adam; Martin, Richard; Mathy, Jon A; Cebon, Jonathan S ; Black, Michael A; Brooks, Anna E S; Dunbar, P Rod |
| 23 | Apr-2020 | Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. | Cebon, Jonathan S ; Gore, Martin; Thompson, John F; Davis, Ian D; McArthur, Grant A; Walpole, Euan; Smithers, Mark; Cerundolo, Vincenzo; Dunbar, P Rod; MacGregor, Duncan; Fisher, Cyril; Millward, Michael; Nathan, Paul; Findlay, Michael P N; Hersey, Peter; Evans, T R Jeffry; Ottensmeier, Christian Hermann; Marsden, Jeremy; Dalgleish, Angus G; Corrie, Pippa G; Maria, Marples; Brimble, Margaret; Williams, Geoff; Winkler, Sintia; Jackson, Heather M; Endo-Munoz, Liliana; Tutuka, Candani S A; Venhaus, Ralph; Old, Lloyd J; Haack, Dennis; Maraskovsky, Eugene; Behren, Andreas; Chen, Weisan |
| 24 | Apr-2020 | A distinct pre-treatment immune gene signature in lentigo maligna is associated with imiquimod response. | Halse, Heloise; Caramia, Franco; McLean, Catriona A; Wang, Minyu; Aw Yeang, Han Xian; Keam, Simon P; Behren, Andreas; Ly, Lena; Haskett, Martin; Cebon, Jonathan S ; McArthur, Grant A; Neeson, Paul J; Mar, Victoria J |
| 25 | 7-Feb-2020 | Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells. | Rigau, Marc; Ostrouska, Simone; Fulford, Thomas S; Johnson, Darryl N; Woods, Katherine; Ruan, Zheng; McWilliam, Hamish E G; Hudson, Christopher; Tutuka, Candani; Wheatley, Adam K; Kent, Stephen J; Villadangos, Jose A; Pal, Bhupinder; Kurts, Christian; Simmonds, Jason; Pelzing, Matthias; Nash, Andrew D; Hammet, Andrew; Verhagen, Anne M; Vairo, Gino; Maraskovsky, Eugene; Panousis, Con; Gherardin, Nicholas A; Cebon, Jonathan S ; Godfrey, Dale I; Behren, Andreas; Uldrich, Adam P |
| 26 | Feb-2020 | Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma. | Wang, Jing; Wuethrich, Alain; Sina, Abu Ali Ibn; Lane, Rebecca E; Lin, Lynlee L; Wang, Yuling; Cebon, Jonathan S ; Behren, Andreas; Trau, Matt |
| 27 | Oct-2019 | Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. | Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; Cebon, Jonathan S ; Ferrucci, Pier Francesco; Aglietta, Massimo; Neyns, Bart; Chiarion-Sileni, Vanna; Lindsay, Colin R; Del Vecchio, Michele; Linardou, Helen; Merelli, Barbara; Tonini, Giuseppe; Atkinson, Victoria; Freivogel, Klaus; Stein, Dara; Dalland, Lindi; Lau, Mike; Legenne, Philippe; Queirolo, Paola; Millward, Michael |
| 28 | 5-Sep-2019 | Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. | Gunjur, Ashray ; Klein, Oliver ; Kee, Damien ; Cebon, Jonathan S |
| 29 | Aug-2019 | A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. | Arulananda, Surein; Parakh, Sagun ; Palmer, Jodie ; Goodwin, Mark D ; Andrews, Miles C; Cebon, Jonathan S |
| 30 | May-2019 | Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. | Gray, Elin S; Witkowski, Tom ; Pereira, Michelle; Calapre, Leslie; Herron, Karl; Irwin, Darryl; Chapman, Brett; Khattak, Muhammad A; Raleigh, Jeanette; Hatzimihalis, Athena; Cebon, Jonathan S ; Sandhu, Shahneen; McArthur, Grant A; Millward, Michael; Ziman, Melanie; Dobrovic, Alexander ; Wong, Stephen Q |
| 31 | 24-Apr-2019 | BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. | Lee, Erinna F; Harris, Tiffany J ; Tran, Sharon; Evangelista, Marco; Arulananda, Surein; John, Thomas ; Ramnac, Celeste; Hobbs, Chloe; Zhu, Haoran; Gunasingh, Gency; Segal, David; Behren, Andreas; Cebon, Jonathan S ; Dobrovic, Alexander ; Mariadason, John M ; Strasser, Andreas; Rohrbeck, Leona; Haass, Nikolas K; Herold, Marco J; Fairlie, W Douglas |
| 32 | Feb-2019 | Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. | Parakh, Sagun ; Randhawa, Manreet; Nguyen, Bella; Warburton, Lydia; Hussain, Mohammad Akhtar; Cebon, Jonathan S ; Millward, Michael; Yip, Desmond; Ali, Sayed |
| 33 | Dec-2018 | Perspective: cancer vaccines in the era of immune checkpoint blockade. | Cebon, Jonathan S |
| 34 | 22-Nov-2018 | Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. | Liew, David F L ; Leung, Jessica L Y ; Liu, Bonnia ; Cebon, Jonathan S ; Frauman, Albert G ; Buchanan, Russell R C |
| 35 | 12-Nov-2018 | Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. | Mitchell, Emma L; Lau, Peter Kar Han; Khoo, Chloe; Liew, David F; Leung, Jessica; Liu, Bonnia ; Rischin, Adam; Frauman, Albert G ; Kee, Damien ; Smith, Kortnye; Brady, Benjamin; Rischin, Danny; Gibson, Andrew; Mileshkin, Linda; Klein, Oliver ; Weickhardt, Andrew; Arulananda, Surein; Shackleton, Mark; McArthur, Grant; Östör, Andrew; Cebon, Jonathan S ; Solomon, Benjamin; Buchanan, Russell R C ; Wicks, Ian P; Lo, Serigne; Hicks, Rodney J; Sandhu, Shahneen |
| 36 | 6-Nov-2018 | Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. | Bethune, Michael T; Li, Xiao-Hua; Yu, Jiaji; McLaughlin, Jami; Cheng, Donghui; Mathis, Colleen; Moreno, Blanca Homet; Woods, Katherine; Knights, Ashley J; Garcia-Diaz, Angel; Wong, Stephanie; Hu-Lieskovan, Siwen; Puig-Saus, Cristina; Cebon, Jonathan S ; Ribas, Antoni; Yang, Lili; Witte, Owen N; Baltimore, David |
| 37 | Nov-2018 | Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma. | Kanatsios, Stefanos; Melanoma Project, Melbourne; Li Wai Suen, Connie S N; Cebon, Jonathan S ; Gyorki, David E |
| 38 | 24-Jul-2018 | Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma. | Halse, H; Colebatch, A J; Petrone, P; Henderson, M A; Mills, J K; Snow, H; Westwood, J A; Sandhu, S; Raleigh, J M; Behren, Andreas; Cebon, Jonathan S ; Darcy, P K; Kershaw, M H; McArthur, G A; Gyorki, D E; Neeson, P J |
| 39 | Apr-2018 | Characterising the phenotypic evolution of circulating tumour cells during treatment. | Tsao, Simon Chang-Hao; Wang, Jing; Wang, Yuling; Behren, Andreas; Cebon, Jonathan S ; Trau, Matt |
| 40 | 2018 | Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide. | Chan, Kok Fei; Gully, Benjamin S; Gras, Stephanie; Beringer, Dennis X; Kjer-Nielsen, Lars; Cebon, Jonathan S ; McCluskey, James; Chen, Weisan; Rossjohn, Jamie |
Loading...
2
0
20
0
false
0000-0002-3898-950x